There's an excellent article in this morning's New York Times on the quest by the Cochrane group to determine the efficacy of Tamiflu, which is part of a bigger story on how pharmaceutical companies selectively release data regarding their products. It demonstrates how epidemiology can involve more than just data analysis and how political activism is sometimes required to find the data to answer basic questions.
Photo: Dr. Tom Jefferson by Chris Warde-Jones for the New York Times.
Pondering vexing issues in infection prevention and control
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
This is a guest post by Jorge Salinas, MD, Hospital Epidemiologist at the University of Iowa Hospitals & Clinics. There is virtually no...
-
I’m surprised that we can’t stop arguing about the modes of SARS-CoV-2 transmission, despite the fact that most experts (including our frie...

No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.